These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 38101609)

  • 61. A patent review of SHP2 allosteric inhibitors (2018-present).
    Petrocchi A; Ciammaichella A
    Expert Opin Ther Pat; 2024 May; 34(5):383-396. PubMed ID: 38842843
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Tyrosine phosphoproteomics identifies both codrivers and cotargeting strategies for T790M-related EGFR-TKI resistance in non-small cell lung cancer.
    Yoshida T; Zhang G; Smith MA; Lopez AS; Bai Y; Li J; Fang B; Koomen J; Rawal B; Fisher KJ; Chen YA; Kitano M; Morita Y; Yamaguchi H; Shibata K; Okabe T; Okamoto I; Nakagawa K; Haura EB
    Clin Cancer Res; 2014 Aug; 20(15):4059-4074. PubMed ID: 24919575
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer.
    Yochum ZA; Cades J; Wang H; Chatterjee S; Simons BW; O'Brien JP; Khetarpal SK; Lemtiri-Chlieh G; Myers KV; Huang EH; Rudin CM; Tran PT; Burns TF
    Oncogene; 2019 Jan; 38(5):656-670. PubMed ID: 30171258
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Acquired EGFR L718V mutation mediates resistance to osimertinib in non-small cell lung cancer but retains sensitivity to afatinib.
    Liu Y; Li Y; Ou Q; Wu X; Wang X; Shao YW; Ying J
    Lung Cancer; 2018 Apr; 118():1-5. PubMed ID: 29571986
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Oncogene swap as a novel mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor in lung cancer.
    Mizuuchi H; Suda K; Murakami I; Sakai K; Sato K; Kobayashi Y; Shimoji M; Chiba M; Sesumi Y; Tomizawa K; Takemoto T; Sekido Y; Nishio K; Mitsudomi T
    Cancer Sci; 2016 Apr; 107(4):461-8. PubMed ID: 26845230
    [TBL] [Abstract][Full Text] [Related]  

  • 66.
    Nakatani K; Yamaoka T; Ohba M; Fujita KI; Arata S; Kusumoto S; Taki-Takemoto I; Kamei D; Iwai S; Tsurutani J; Ohmori T
    Mol Cancer Ther; 2019 Jan; 18(1):112-126. PubMed ID: 30322949
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Targeting Acquired and Intrinsic Resistance Mechanisms in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer.
    Shah MP; Neal JW
    Drugs; 2022 Apr; 82(6):649-662. PubMed ID: 35412115
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC).
    Martinez-Marti A; Felip E; Matito J; Mereu E; Navarro A; Cedrés S; Pardo N; Martinez de Castro A; Remon J; Miquel JM; Guillaumet-Adkins A; Nadal E; Rodriguez-Esteban G; Arqués O; Fasani R; Nuciforo P; Heyn H; Villanueva A; Palmer HG; Vivancos A
    Ann Oncol; 2017 Oct; 28(10):2451-2457. PubMed ID: 28961841
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Mutant-Selective Irreversible EGFR Inhibitor, Naquotinib, Inhibits Tumor Growth in NSCLC Models with EGFR-Activating Mutations, T790M Mutation, and AXL Overexpression.
    Tanaka H; Sakagami H; Kaneko N; Konagai S; Yamamoto H; Matsuya T; Yuri M; Yamanaka Y; Mori M; Takeuchi M; Koshio H; Hirano M; Kuromitsu S
    Mol Cancer Ther; 2019 Aug; 18(8):1366-1373. PubMed ID: 31092564
    [TBL] [Abstract][Full Text] [Related]  

  • 70. AXL/MET dual inhibitor, CB469, has activity in non-small cell lung cancer with acquired resistance to EGFR TKI with AXL or MET activation.
    Yang YM; Jang Y; Lee SH; Kang B; Lim SM
    Lung Cancer; 2020 Aug; 146():70-77. PubMed ID: 32521387
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
    Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
    BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Precision Targeted Therapy with BLU-667 for
    Subbiah V; Gainor JF; Rahal R; Brubaker JD; Kim JL; Maynard M; Hu W; Cao Q; Sheets MP; Wilson D; Wilson KJ; DiPietro L; Fleming P; Palmer M; Hu MI; Wirth L; Brose MS; Ou SI; Taylor M; Garralda E; Miller S; Wolf B; Lengauer C; Guzi T; Evans EK
    Cancer Discov; 2018 Jul; 8(7):836-849. PubMed ID: 29657135
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Phosphoproteomics Reveals MAPK Inhibitors Enhance MET- and EGFR-Driven AKT Signaling in KRAS-Mutant Lung Cancer.
    Kim JY; Welsh EA; Fang B; Bai Y; Kinose F; Eschrich SA; Koomen JM; Haura EB
    Mol Cancer Res; 2016 Oct; 14(10):1019-1029. PubMed ID: 27422710
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Data-Driven Computational Modeling Identifies Determinants of Glioblastoma Response to SHP2 Inhibition.
    Day EK; Zhong Q; Purow B; Lazzara MJ
    Cancer Res; 2021 Apr; 81(8):2056-2070. PubMed ID: 33574084
    [TBL] [Abstract][Full Text] [Related]  

  • 75. CRISPR Screening Identifies Mechanisms of Resistance to KRASG12C and SHP2 Inhibitor Combinations in Non-Small Cell Lung Cancer.
    Prahallad A; Weiss A; Voshol H; Kerr G; Sprouffske K; Yuan T; Ruddy D; Meistertzheim M; Kazic-Legueux M; Kottarathil T; Piquet M; Cao Y; Martinuzzi-Duboc L; Buhles A; Adler F; Mannino S; Tordella L; Sansregret L; Maira SM; Graus Porta D; Fedele C; Brachmann SM
    Cancer Res; 2023 Dec; 83(24):4130-4141. PubMed ID: 37934115
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Resistance to allosteric SHP2 inhibition in FGFR-driven cancers through rapid feedback activation of FGFR.
    Lu H; Liu C; Huynh H; Le TBU; LaMarche MJ; Mohseni M; Engelman JA; Hammerman PS; Caponigro G; Hao HX
    Oncotarget; 2020 Jan; 11(3):265-281. PubMed ID: 32076487
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer.
    Sato H; Yamamoto H; Sakaguchi M; Shien K; Tomida S; Shien T; Ikeda H; Hatono M; Torigoe H; Namba K; Yoshioka T; Kurihara E; Ogoshi Y; Takahashi Y; Soh J; Toyooka S
    Cancer Sci; 2018 Oct; 109(10):3183-3196. PubMed ID: 30098066
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Exon 16-Skipping HER2 as a Novel Mechanism of Osimertinib Resistance in EGFR L858R/T790M-Positive Non-Small Cell Lung Cancer.
    Hsu CC; Liao BC; Liao WY; Markovets A; Stetson D; Thress K; Yang JC
    J Thorac Oncol; 2020 Jan; 15(1):50-61. PubMed ID: 31557536
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes.
    Mu Y; Hao X; Xing P; Hu X; Wang Y; Li T; Zhang J; Xu Z; Li J
    J Cancer Res Clin Oncol; 2020 Sep; 146(9):2427-2433. PubMed ID: 32385709
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.
    Nguyen KS; Kobayashi S; Costa DB
    Clin Lung Cancer; 2009 Jul; 10(4):281-9. PubMed ID: 19632948
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.